Woodruff Lab - Services

We specialise in Parkinson’s disease, motor neuron disease; MND (amyotrophic lateral sclerosis; ALS) and neuroinflammation assays.

• Capacity in preclinical drug testing (efficacy) indisease models, or target validation studies.
• Range of state-of-the-art disease models accepted by funders and regulators as best-practice preclinical efficacy models.
• An extensive range of both standardised and novelbehavioural and pathological analyses that can becustomised to suit individual requirements.
• Can be coupled with pharmacodynamic and pharmacokinetic data from the same animal to maximisedata output and assay validation.
• Successful record in completing industry contracts,with two drugs undergoing human clinical trialsafter successful testing in preclinical models.
• Strong publication track record in preclinical neurodegenerative disease animal studies.
• Offer opportunities for leverage funding throughnon-diluting grant funding.
• Competitive rates for both fee-for-service or collaborative research projects.

In vivo models available

• Neuroinflammation endotoxin model (peripheral orcentral induction)
• Parkinson’s disease 6-hydroxydopamine (6-OHDA) model
• Parkinson’s disease synuclein pre-formed fibril (PFF-Syn) model
• Motor neuron disease SOD1G93A transgenic mouse model
• Motor neuron disease TDP43-transgenic mouse models

In vitro/ex vivo models available

• Primary human microglia neuroinflammation assays (derived from human blood)
• Primary mouse microglia neuroinflammation assays (derived from mice CNS tissue)

Neurotransmitter and Metabolite Quantitation

• We offer new methods to simultaneously measure a range of neurotransmitters, metabolites, vitamins, and short-chain fatty acids from any sample.
• We utilise state-of-the-art LC-MS/MS methodology to provide full quantitation of analytes coupled with standard curves.
• We have the ability to determine concentrations in a wide range of biological fluids or tissues from any animal or human species.
• Analyses can be easily coupled with efficacy studies in neurodegenerative disease or psychiatry models to allow full quantitation of drug activities.